MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- SUN PHARMA
SUN PHARMA Share Price (SUNP)
Here is the latest stock price and chart of Sun Pharma. For more details, see the Sun Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Sep 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)416.80 | Open (Rs) 424.65 | High (Rs) 424.85 | Low (Rs) 414.45 |
| % Change-0.92 | Volume 263,471 | Value (Rs) 110,242,528 | 52-Week H/L 657.00 / 350.40 |
| Live NSE Quotes | Sep 18, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)416.80 | Open (Rs) 423.90 | High (Rs) 424.60 | Low (Rs) 414.25 |
| % Change-0.92 | Volume 3,728,621 | Value (Rs) 1,560,619,059 | 52-Week H/L 657.25 / 344.55 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 14.86 | P/E Ratio (x) 28.05 | Market Cap (Rs m) 1,003,134.65 | P/BV (x) 2.42 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA Share Price Today:
SUN PHARMA last traded price was down 0.9% to Rs 416.8 on the BSE. On the NSE, SUN PHARMA last traded price was down 0.9% to Rs 416.8. The total volume of shares traded was 4.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.3%. And the benchmark S&P BSE SENSEX was at 36,563.9 (up 0.2%).
Over the last 30 days, the SUN PHARMA share price is down 2.1%. And over the last one year, SUN PHARMA share price is down 35.1%.
|
| |
Today's Market
Rising Petrol and Diesel Prices, DHFL Saga, and Top Cues in Focus Today(Pre-Open)
Indian share markets ended their trading session marginally higher yesterday. On the sectoral front, gains were seen in the metal sector and realty sector.
Related Views On News
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India (The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Recession Proof Stock You Can Bet On (Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
This Company Will Do Well Despite the Slowdown (The 5 Minute Wrapup)
Sep 11, 2019How financial inclusion provides a big runway for this stock recommendation.
A Rare Opportunity to Buy the Top 5 Stocks in the Market (The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
The 5 Best Trading Opportunities I've Spotted (Profit Hunter)
Sep 13, 2019These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.
MoreTRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.